An unresolved question for the understanding of Alzheimer's disease (AD) pathophysiology
is why a significant percentage of amyloid-β (Aβ)-positive cognitively unimpaired (CU) …

Alzheimer's disease (AD) causes unrelenting, progressive cognitive impairments, but its
course is heterogeneous, with a broad range of rates of cognitive decline. The spread of tau …

Abstract Development of tau-based therapies for Alzheimer's disease requires an
understanding of the timing of disease-related changes in tau. We quantified the …

Alzheimer's disease (AD) is characterized by the spread of tau pathology throughout the
cerebral cortex. This spreading pattern was thought to be fairly consistent across individuals …

Alzheimer's disease (AD) pathology is estimated to develop many years before detectable
cognitive decline. Fluid and imaging biomarkers may identify people in early symptomatic …

Patients with Alzheimer's disease (AD) present with both extracellular amyloid-β (Aβ)
plaques and intracellular tau-containing neurofibrillary tangles in the brain. For many years …

The global epidemic of Alzheimer disease (AD) is worsening, and no approved treatment
can revert or arrest progression of this disease. AD pathology is characterized by the …

Alzheimer's disease (AD) is characterized by extracellular amyloid-β (Aβ) plaques and
intracellular tau inclusions. However, the exact mechanistic link between these two AD …

Staging amyloid-beta (Aβ) pathophysiology according to the intensity of neurodegeneration
could identify individuals at risk for cognitive decline in Alzheimer's disease (AD). In blood …

For optimal design of anti-amyloid-β (Aβ) and anti-tau clinical trials, we need to better
understand the pathophysiological cascade of Aβ-and tau-related processes. Therefore, we …